Physician profile
Luis Chavez
NPI 1295224905
$3,446.78
in general payments reported to CMS, 2019-2025
18 companies · $614 in 2025
The $614 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $546 · 2023: $1,350 · 2024: $938 · 2025: $614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,016 · Travel and Lodging: $885.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,015.63 |
| Travel and Lodging | $885.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Wilson Cook Medical Incorporated | $772.94 | 2023 | Fusion |
| Takeda Pharmaceuticals U.S.A., INC. | $414.11 | 2022-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $322.68 | 2022-2025 | Xifaxan |
| Gilead Sciences, INC. | $313.74 | 2022-2025 | |
| Madrigal Pharmaceuticals | $295.51 | 2024 | Resmetirom |
| Abbvie INC. | $263.03 | 2024-2025 | |
| Cook Medical LLC | $214.30 | 2023 | Fusion |
| Ardelyx, INC. | $173.59 | 2023 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $162.35 | 2022-2023 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $135.03 | 2024 | Voquezna |
| Medtronic, INC. | $83.76 | 2022-2024 | Gi Genius |
| Genzyme Corporation | $71.42 | 2025 | |
| Pfizer INC. | $70.85 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $52.11 | 2025 | Dupixent |
| Celltrion USA INC. | $38.08 | 2025 | Vegzelma |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $30.51 | 2024 | Spyglass |
| Olympus America INC. | $17.89 | 2024 | Endoclot Sis, Olympus |
| Janssen Biotech, INC. | $14.88 | 2024 | Stelara |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Chavez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.